Published in Infect Immun on April 01, 1981
Treatment of alveolar macrophages with cytochalasin D inhibits uptake and subsequent growth of Legionella pneumophila. Infect Immun (1986) 1.53
Binding of Legionella pneumophila to macrophages increases cellular cytokine mRNA. Infect Immun (1994) 1.08
Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl (1968) 60.35
The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal secretion for neutrophils. J Exp Med (1976) 7.57
Ability of polymorphonuclear leukocytes to orient in gradients of chemotactic factors. J Cell Biol (1977) 7.13
The range of attractant concentrations for bacterial chemotaxis and the threshold and size of response over this range. Weber law and related phenomena. J Gen Physiol (1973) 6.92
The mechanism of action of colchicine. Colchicine binding to sea urchin eggs and the mitotic apparatus. J Cell Biol (1967) 6.85
Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1977) 5.87
The detertent-resistant cytoskeleton of tissue culture cells includes the nucleus and the microfilament bundles. Exp Cell Res (1977) 3.84
Demonstration of a receptor on rabbit neutrophils for chemotactic peptides. Biochem Biophys Res Commun (1977) 3.81
Preparation of mammalian polyribosomes with the detergent Nonidet P-40. Biochim Biophys Acta (1967) 3.81
Action of cytochalasin D on cells of established lines. I. Early events. J Cell Biol (1974) 2.64
Isolation of H-2 alloantigens solubilized by the detergent NP-40. J Immunol (1971) 2.26
Cytochalasin B. IV. Inhibition and stimulation of chemotaxis of rabbit and human polymorphonuclear leukocytes. J Immunol (1972) 2.04
Changes in ionic movements across rabbit polymorphonuclear leukocyte membranes during lysosomal enzyme release. Possible ionic basis for lysosomal enzyme release. J Cell Biol (1977) 1.94
Biochemical studies on the mode of action of cytochalasin B. Cytochalasin B binding to red cell membrane in relation to glucose transport. J Biol Chem (1974) 1.86
Use of cytochalasin B to distinguish between early and late events in neutrophil activation. Biochim Biophys Acta (1980) 1.56
Receptors for thyrotropin-releasing hormone in prolactin producing rat pituitary cells in culture. J Biol Chem (1973) 1.35
Urate crystal-induced chemotactic factor: isolation and partial characterization. J Clin Invest (1976) 1.34
Magnesium-dependent adenosine triphosphatase as a marker enzyme for the plasma membrane of human polymorphonuclear leukocytes. Infect Immun (1977) 1.25
Demonstration of a specific neutrophil receptor for a cell-derived chemotactic factor. J Clin Invest (1979) 1.20
Cell surface receptors for insulin and human growth hormone. Effect of microtubule and microfilament modifiers. J Biol Chem (1976) 1.09
The action of colchicine in acute gout. Arthritis Rheum (1965) 1.07
Modulation of macrophage C3b receptor function by cytochalasin-sensitive structures. J Immunol (1977) 1.05
Rod-like elements from actin-containing microfilament bundles observed in cultured cells after treatment with cytochalasin A (CA). Exp Cell Res (1977) 1.03
Cytochalasin binding in lymphocytes and polymorphonuclear leukocytes. Exp Cell Res (1976) 0.86
Pancreatic acinar cell changes induced by caerulein, vinblastine, deuterium oxide, and cytochalasin B in vitro. Lab Invest (1978) 0.82
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant (2007) 2.74
Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet (2000) 2.72
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2005) 2.07
Breakdown of cartilage proteinpolysaccharide by lysosomes. Arthritis Rheum (1968) 1.99
Malignant coronary artery disease in young Asian Indians: thoughts on pathogenesis, prevention, and therapy. Coronary Artery Disease in Asian Indians (CADI) Study. Clin Cardiol (1995) 1.99
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89
Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. Bone Marrow Transplant (2009) 1.60
Meeting of the International Working Group on Coronary Artery Disease in South Asians. 24 March 1996, Orlando, Florida, USA. Indian Heart J (1997) 1.58
Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome. Br J Anaesth (2012) 1.58
Arthritis induced in rabbits by lysates of granulocyte lysosomes. Arthritis Rheum (1969) 1.55
Induction of a transient elevation in intracellular levels of adenosine-3',5'-cyclic monophosphate by chemotactic factors: an early event in human neutrophil activation. J Immunol (1980) 1.54
Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant (2007) 1.51
Chemotactic factor-induced generation of superoxide radicals by human neutrophils: evidence for the role of sodium. J Immunol (1979) 1.51
Generation of superoxide radicals by human peripheral neutrophils activated by chemotactic factor. Evidence for the role of calcium. J Lab Clin Med (1979) 1.48
Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplant (1995) 1.45
Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant (1999) 1.45
Fatal systemic lupus erythematosus in patient taking oral iron chelator L1. Lancet (1991) 1.44
How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant (2004) 1.41
Chemotactic factor-induced generation of superoxide radicals by human neutrophils: effect of metabolic inhibitors and antiinflammatory drugs. Arthritis Rheum (1979) 1.37
The arthritis of sarcoidosis. Arthritis Rheum (1969) 1.36
Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant (2007) 1.34
Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation (1977) 1.24
Age is not a prognostic variable with autotransplants for multiple myeloma. Blood (1999) 1.23
Demonstration of a specific neutrophil receptor for a cell-derived chemotactic factor. J Clin Invest (1979) 1.20
Letter: Diagonal ear-lobe crease as a coronary risk factor. N Engl J Med (1974) 1.20
Predialysis nephrologist care and access to kidney transplantation in the United States. Am J Transplant (2007) 1.16
Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol (1997) 1.14
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood (1998) 1.12
Sodium and potassium fluxes and membrane potential of human neutrophils: evidence for an electrogenic sodium pump. J Gen Physiol (1982) 1.10
Comparative hemodynamic effects of intravenous nitroprusside and oral prazosin in refractory heart failure. Am J Cardiol (1978) 1.09
Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. 3. Role of tachycardia stress and propranolol. Circulation (1978) 1.08
Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease. Am Heart J (1977) 1.07
Medical-surgical aspects of left main coronary artery disease. J Thorac Cardiovasc Surg (1976) 1.06
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol (1998) 1.05
Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leuk Lymphoma (1999) 1.05
Platelet function studies in coronary artery disease. V. Evidence for enhanced platelet microthrombus formation activity in acute myocardial infarction. Am J Cardiol (1979) 1.05
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant (2000) 1.04
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant (2006) 1.04
Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem Pharmacol (1984) 1.04
Dissociation of the neutrophill functions of exocytosis and chemotaxis. J Lab Clin Med (1978) 1.03
Stimulus-specific deactivation of chemotactic factor-induced cyclic AMP response and superoxide generation by human neutrophils. J Clin Invest (1980) 1.03
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer (2007) 1.03
Measuring quality of care for rheumatic diseases using an electronic medical record. Ann Rheum Dis (2008) 1.02
Evaluation of immunogenicity and safety of Genevac B: a new recombinant hepatitis B vaccine in comparison with Engerix B and Shanvac B in healthy adults. Indian J Med Microbiol (2007) 1.02
Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant (2004) 1.01
Joint manifestations of sickle cell disease. Medicine (Baltimore) (1974) 1.00
Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant (2001) 0.99
Thalidomide in cancer. Biomed Pharmacother (2002) 0.98
Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant (2002) 0.97
Comparative effects of nitroprusside and nitroglycerin on platelet aggregation in patients with heart failure. J Cardiovasc Pharmacol (1980) 0.96
Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood (2000) 0.95
Determination of a specific receptor for formyl-methionyl-leucyl-phenylalanine on th pulmonary alveolar macrophage and its relationship to chemotaxis and superoxide production. J Lab Clin Med (1981) 0.95
Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant (2004) 0.94
Immunoprofile of Hodgkin's lymphoma in India. Indian J Cancer (2008) 0.94
A phospholipase A2-activating protein (PLAP) stimulates human neutrophil aggregation and release of lysosomal enzymes, superoxide, and eicosanoids. J Immunol (1989) 0.93
Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol (1987) 0.93
Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant (2002) 0.93
In vivo validation of a thermodilution method to determine regional left ventricular blood flow in patients with coronary disease. Circulation (1978) 0.92
Eicosapentaenoic acid: its relevance in atherosclerosis and coronary artery disease. Am J Cardiol (1987) 0.92
The arthritis of leukemia. Arthritis Rheum (1973) 0.92
Stimulation of the respiratory burst in human neutrophils by crystal phagocytosis. Arthritis Rheum (1982) 0.91
Studies on crystal-induced chemotactic factor. I. Requirement for protein synthesis and neutral protease activity. J Lab Clin Med (1974) 0.91
Evidence that the functional responses of human neutrophils occur independently of transient elevations in cyclic AMP levels. J Cyclic Nucleotide Protein Phosphor Res (1983) 0.91
Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant (2001) 0.91
Mucus secretion in gastric ulcer patients treated with tripotassium dicitrato bismuthate (De-Nol). Br J Clin Pract (1983) 0.91
Anti-myeloma activity of pamidronate in vivo. Br J Haematol (1998) 0.91
Hemopexin metabolism in sickle-cell disease, porphyrias and control subjects--effects of heme injection. N Engl J Med (1974) 0.91
Effect of altered lymphocyte function on immunologic disorders in NZB/NZW mice. III. Acceleration of disease by thymosin. Arthritis Rheum (1978) 0.90
Anti-inflammatory effect of the trypsin-kallikrein inhibitor in acute arthritis induced by urate crystals in rabbits. J Lab Clin Med (1970) 0.90
Studies of cell death (apoptosis) and cell division in leprosy granulomas. Int J Lepr Other Mycobact Dis (1986) 0.90
Opera-glass deformity and tendon rupture in a patient with systemic lupus erythematosus. Clin Rheumatol (1985) 0.90
Evidence for the role of superoxide radicals in neutrophil-mediated cytotoxicity. Immunology (1979) 0.89
Laparoscopic fenestration and modified marsupialization of posttraumatic splenic cysts using a harmonic scalpel. Surg Endosc (2001) 0.89
Circulating platelet aggregates in sickle cell disease patients with and without vaso-occlusion. Stroke (1980) 0.89
Heterologous receptor population for a chemotactic factor F-Met-Leu-Phe on the human neutrophil. Effect of pH and temperature. Inflammation (1983) 0.89
Studies on crystal-induced chemotactic factor. II. Role of phagocytosis. J Lab Clin Med (1975) 0.89
Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant (2010) 0.89
Benzodiazepine use and mortality of incident dialysis patients in the United States. Kidney Int (2007) 0.89
Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest (1979) 0.89
Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission. Bone Marrow Transplant (1996) 0.89
Platelet function in hypertension and effect of therapy. Am J Cardiol (1981) 0.88
A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant (2000) 0.88
Clinical outcome after treatment of rest angina with calcium blockers: comparative experience during the initial year of therapy with diltiazem, nifedipine, and verapamil. Am Heart J (1983) 0.88
Urate crystal arthritis in animals lacking Hageman factor. Arthritis Rheum (1974) 0.88
Type 1 angiotensin II receptors in rat and human sperm. J Endocrinol (1995) 0.87
Thalidomide in cancer: potential uses and limitations. BioDrugs (2001) 0.87
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer (2000) 0.87
Current concepts of the mechanism of acute inflammation in gouty arthritis. Arthritis Rheum (1975) 0.86
A proposed model for chemotactic deactivation: evidence for microtubule modulation of polymorphonuclear leukocyte chemotaxis. J Lab Clin Med (1979) 0.86
Calcium pyrophosphate dihydrate (CPPD) crystal-induced chemotactic factor: subcellular localization, role of protein synthesis and phagocytosis. J Lab Clin Med (1977) 0.86
Induction of arthritis by purified cell-derived chemotactic factor: role of chemotaxis and vascular permeability. J Clin Invest (1977) 0.86